Repligen (NASDAQ:RGEN) Stock Price Up 5.4% – Still a Buy?

Repligen Co. (NASDAQ:RGEN)’s share price rose 5.4% during mid-day trading on Tuesday . The stock traded as high as $144.49 and last traded at $144.38. Approximately 133,624 shares changed hands during trading, a decline of 79% from the average daily volume of 637,420 shares. The stock had previously closed at $136.99.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on RGEN. Canaccord Genuity Group started coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Wolfe Research initiated coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Royal Bank of Canada increased their target price on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. JPMorgan Chase & Co. upped their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Finally, StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $181.00.

Repligen Price Performance

The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock has a market capitalization of $8.03 billion, a P/E ratio of -280.07, a P/E/G ratio of 4.54 and a beta of 0.95. The firm has a fifty day moving average of $157.09 and a two-hundred day moving average of $148.51.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The firm had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. On average, analysts predict that Repligen Co. will post 1.72 EPS for the current year.

Hedge Funds Weigh In On Repligen

A number of hedge funds have recently made changes to their positions in the stock. Polar Asset Management Partners Inc. lifted its stake in Repligen by 76.9% during the fourth quarter. Polar Asset Management Partners Inc. now owns 6,900 shares of the biotechnology company’s stock worth $993,000 after purchasing an additional 3,000 shares in the last quarter. GTS Securities LLC acquired a new position in Repligen during the 4th quarter worth about $264,000. Gordian Capital Singapore Pte Ltd purchased a new position in Repligen during the 4th quarter valued at about $259,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Repligen by 12.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 235,343 shares of the biotechnology company’s stock valued at $33,875,000 after acquiring an additional 26,733 shares in the last quarter. Finally, Two Sigma Advisers LP increased its stake in Repligen by 6.7% during the fourth quarter. Two Sigma Advisers LP now owns 134,800 shares of the biotechnology company’s stock worth $19,403,000 after purchasing an additional 8,500 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.